ReviewNaunyn-Schmiedeberg's archives of pharmacology2025
A review of the extraction technologies, structural characterization, chemical modification, and pharmacological effects of Ganoderma lucidum polysaccharides.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mechanism of Ganoderma lucidum polysaccharides in the mangement of diabetes and its complications.Frontiers in pharmacology · 2026Pooled it
- From Remedy to Therapy: Confronting the Bioavailability Bottleneck inPharmaceuticals (Basel, Switzerland) · 2026Review
- AClinical, cosmetic and investigational dermatology · 2026Article
- From functional foods to immunotherapeutic agents: mechanistic insights into medicinal mushroom bioactives in chronic inflammation management.Frontiers in nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ganoderma lucidum (GL) is a medicinal and edible fungal material with a long history. Ganoderma lucidum polysaccharides (GLPs), as one of the primary bioactive components in GL, exhibit multiple pharmacological effects including anti-tumor, anti-inflammatory, immunomodulatory, antioxidant, and metabolic regulatory activities. While the monosaccharide composition and structural characteristics of GLPs are influenced by extraction methods and chemical modifications, the relationship between their structural features and bioactivities remains unclear. This review summarizes recent advances in the extraction, preparation, structural analysis, chemical modification, emerging technologies, and clinical applications of GLPs, providing insights for further exploration and elucidation of their structure-activity relationships. Additionally, the pharmacological potential of GLPs is systematically reviewed, highlighting their promising applications in pharmaceutical development and functional food innovation. This comprehensive analysis offers valuable references for advancing the utilization of GLPs in medicinal and nutraceutical fields.
Indexed as
Identifiers
40719895What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.